Qinghai Spring Medicinal Resources Technology Co., Ltd.
600381.SS · SHH
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.69 | 0.44 | -0.67 | -0.02 |
| FCF Yield | -0.42% | 0.66% | -3.04% | 2.82% |
| EV / EBITDA | -831.70 | 1,695.69 | 426.92 | -16.61 |
| Quality | ||||
| ROIC | -0.37% | -0.59% | 0.87% | -10.10% |
| Gross Margin | 27.03% | 62.99% | 60.63% | -10.43% |
| Cash Conversion Ratio | 1.98 | -2.27 | -8.74 | – |
| Growth | ||||
| Revenue 3-Year CAGR | 13.88% | 16.54% | 23.99% | 19.05% |
| Free Cash Flow Growth | -170.97% | 120.85% | -230.90% | 5,714.93% |
| Safety | ||||
| Net Debt / EBITDA | 37.95 | -101.46 | -19.86 | 1.76 |
| Interest Coverage | 0.00 | 10.97 | 53.72 | -1,219.86 |
| Efficiency | ||||
| Inventory Turnover | 0.41 | 0.09 | 0.20 | 0.46 |
| Cash Conversion Cycle | 308.64 | 1,172.65 | 527.37 | 278.20 |